Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Timely G-CSF Administration Is Key for Hematologic AE Management in mPDAC Receiving NALIRIFOX

April 10th 2025

The association between greater hematologic AEs and increased OS necessitates early receipt of G-CSF after NALIRIFOX infusion for patients with PDAC.

Antidiarrheal Medication Is Crucial for Mitigating NALIRIFOX-Related Diarrhea in Metastatic PDAC

April 10th 2025

Diarrhea is common in patients with PDAC treated with NALIRIFOX and can be proactively managed or mitigated to potentially improve survival outcomes.

IO Research Pays Off in MSI-H/dMMR CRC but Misses the Mark in MSS/pMMR Disease

April 6th 2025

Tanios S. Bekaii-Saab, MD, discusses questions that have arisen regarding the use of immunotherapy in patients with MSI-H/dMMR and MSS/pMMR CRC.

Q2 2025: 7 FDA Decisions to Watch in the Realm of Oncology

April 5th 2025

Here is your Q2 2025 preview spotlighting 7 FDA decisions to watch, including upcoming PDUFAs for nivolumab/ipilimumab, belzutifan, UGN-102, avutometinib/defactinib, and more.

AYA Cancer Awareness Week: Patient Support, Multidisciplinary Care Are Key for Management of NETs

April 4th 2025

Jennifer Chan, MD, underscores the importance of early NET diagnosis in young adult and pediatric patients.

OncLive’s FDA Approval Report: The Regulatory Rundown for March 2025

April 2nd 2025

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.

Dr Chan on the Prevalence of Neuroendocrine Tumors in Young-Adult Patients

April 2nd 2025

Jennifer Chan, MD, MPH, discusses the prevalence of neuroendocrine tumors during Adolescent and Young Adult Cancer Awareness Week.

Tovecimig Plus Paclitaxel Meets ORR End Point in Second-Line Biliary Tract Cancer

April 1st 2025

Tovecimig plus paclitaxel improved overall response rate vs paclitaxel alone in second-line advanced biliary tract cancer.

Tislelizumab Plus Chemo Expands First-Line ESCC Treatment Paradigm

March 31st 2025

Nataliya Uboha, MD, PhD, discusses the benefits of expanding the first-line ESCC treatment paradigm with tislelizumab plus chemotherapy.

The OncFive: Top Oncology Articles for the Week of 3/23

March 29th 2025

The FDA cleared therapeutic options in pNETs/epNETs, MIBC, and mCRPC; experts highlight top abstracts ahead of 2025 EBMT; and more from OncLive.

Dr Chan on the FDA Approval of Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

March 28th 2025

Jennifer Chan, MD, MPH, discusses the FDA approval of cabozantinib for previously treated, advanced well-differentiated (extra) pancreatic neuroendocrine tumors.

FDA Approves Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

March 26th 2025

The FDA has approved cabozantinib (Cabometyx) for use in select patients with pancreatic and extra-pancreatic neuroendocrine tumors.

NMPA Approves sNDA for Toripalimab Plus Bevacizumab in Advanced HCC

March 24th 2025

The combination of toripalimab and bevacizumab has been approved in China for the treatment of patients with unresectable or metastatic HCC.

The OncFive: Top Oncology Articles for the Week of 3/16

March 22nd 2025

Pembrolizumab combination gets full approval in select HER2+ gastric/GEJ cancer, PSMA PET imaging agent is cleared for prostate cancer, and more from OncLive.

Improving Outcomes for Patients With Anal Cancer By Raising Awareness

March 21st 2025

For Anal Cancer Awareness Day, Sheela Rao, MBBS, MD, FRCP, discusses present and upcoming treatment strategies, unmet needs, and the future of the field.

Dr Rao on the Current Treatment Landscape in Localized Anal Cancer

March 21st 2025

Sheela Rao, MBBS, MD, FRCP, highlights the current treatment landscape in the localized anal cancer setting for anal cancer Awareness Day, March 21.

PEP-010 Wins FDA Orphan Drug Designation in Metastatic Pancreatic Cancer

March 20th 2025

PEP-010 has been granted an orphan drug designation by the FDA for the treatment of patients with metastatic pancreatic cancer.

FDA Approves Pembrolizumab Plus Trastuzumab/Chemo for PD-L1+, HER2+ Gastric/GEJ Adenocarcinoma

March 19th 2025

The FDA approved pembrolizumab, trastuzumab, and chemotherapy for HER2-positive, PD-L1–positive gastric/GEJ adenocarcinoma.

HLX22 Receives FDA Orphan Drug Designation in Gastric Cancer

March 19th 2025

The FDA has granted orphan drug designation to HLX22 for the treatment of patients with gastric cancer based on positive data from the HLX22-GC-201 study.

Association Between CLDN18 and MUC1 Could Drive Novel Targeted Therapy Options in GI Cancers

March 19th 2025

Aditya Shreenivas, MD, MS, discusses the association between Claudin 18 and MUC1 biomarkers and ongoing targeted therapy challenges.